Julio Rosenstock, MD: Work on World’s First Once-Weekly Basal Insulin Featured on the New England Journal of Medicine Homepage

Julio Rosenstock, MD, has his work spotlighted as the feature article on the New England Journal of Medicine’s homepage. Serving as the lead investigator for Novo Nordisk’s ONWARDS 1 program, Dr. Rosenstock has made remarkable strides in exploring what could be the world’s first once-weekly basal insulin.

“In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A once-weekly basal insulin has the potential to change how we treat people with type 2 diabetes needing basal insulin replacement.”

Read more about this groundbreaking research and view the accompanying summary video here: https://www.nejm.org/doi/full/10.1056/NEJMoa2303208

Posted in

Quality. Continuity. Velocity.